Rapport Therapeutics's top three insider shareholders as of March 23, 2026 are Rock Ventures V, L.P. Third (TenPercentOwner, 8.10Mn shares), Venture Partners Xii, Llc Arch (TenPercentOwner, 3.73Mn shares), Abraham Ceesay (Chief Executive Officer, 576.98K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Rock Ventures V, L.P. Third | 7,135,233 | 969,218 | 10 Jun, 2024 | |
| Venture Partners Xii, Llc Arch | 0 | 3,728,738 | 10 Jun, 2024 | |
| Abraham Ceesay | Chief Executive Officer | 556,247 | 20,729 | 19 Feb, 2026 |
| David Bredt | Chief Scientific Officer | 393,075 | 0 | 19 Feb, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 296,991 | 0 | 05 Jan, 2026 |
| Cheryl Gault | Chief Operating Officer | 169,914 | 0 | 09 Mar, 2026 |
| Reid M Huber | 20,400 | 0 | 15 Sep, 2025 | |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 | 0 | 13 Mar, 2025 |
| Wendy B. Young | 9,500 | 0 | 11 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 05 Mar, 2026 | Cheryl Gault | Common Stock | D | 2,014 | $28.93 | 169,914 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 900 | $28.02 | 394,675 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 3,552 | $29.05 | 558,528 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 5,400 | $28.95 | 389,275 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,281 | $29.80 | 556,247 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,983 | $29.04 | 22,829 | I | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 2,200 | $29.59 | 387,075 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,100 | $29.80 | 20,729 | I | S |
| 19 Feb, 2026 | David Bredt | Common Stock | A | 6,000 | $1.80 | 393,075 | D | M |
| 19 Feb, 2026 | David Bredt | Stock Options (Right to Buy) | D | 6,000 | $0.00 | 88,080 | D | M |
| 02 Feb, 2026 | Jeffrey Sevigny | Stock Option (Right to Buy) | A | 130,000 | $0.00 | 130,000 | D | A |
| 02 Feb, 2026 | Troy A. Ignelzi | Stock Option (Right to Buy) | A | 148,000 | $0.00 | 148,000 | D | A |
| 02 Feb, 2026 | Krishnaswamy Yeleswaram | Stock Option (Right to Buy) | A | 120,000 | $0.00 | 120,000 | D | A |
| 02 Feb, 2026 | Cheryl Gault | Stock Option (Right to Buy) | A | 132,000 | $0.00 | 132,000 | D | A |
| 02 Feb, 2026 | David Bredt | Stock Option (Right to Buy) | A | 103,000 | $0.00 | 103,000 | D | A |
| 02 Feb, 2026 | Abraham Ceesay | Stock Option (Right to Buy) | A | 428,000 | $0.00 | 428,000 | D | A |
| 20 Jan, 2026 | Abraham Ceesay | Common Stock | D | 5,833 | $26.12 | 562,080 | D | S |
| 20 Jan, 2026 | Abraham Ceesay | Common Stock | D | 5,083 | $26.11 | 25,812 | I | S |
| 15 Jan, 2026 | David Bredt | Common Stock | D | 8,300 | $26.83 | 395,775 | D | S |
| 15 Jan, 2026 | David Bredt | Common Stock | D | 200 | $27.40 | 395,575 | D | S |